Investigating the success of an app-led weight loss program

pfit GmbH & Co. KG0 个研究点目标入组 60 人开始时间: 2024年3月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Written informed consent of the study participants after detailed verbal and written explanation of the study content, requirements and risks
•- Ability and willingness to follow the investigator's instructions
•- BMI: 28.0-35.0 kg/m2

•- Severe chronic diseases (diagnosed diabetes, cardiovascular diseases, liver diseases, renal insufficiency, cancer)
•- Chronic diseases of the gastrointestinal tract (especially small intestine, liver, pancreas) and condition following surgery on the gastrointestinal tract; e.g. gastrectomy, sprue, enterocolitis, chronic pancreatitis, cholestasis, short bowel syndrome, chronic inflammatory bowel disease, not: appendicitis, gallstone surgery
•- Surgical procedures to reduce the size of the stomach, gastric banding, gastric balloon
•- Autoimmune diseases (e.g. Crohn's disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis)
•- Regular intake of laxatives
•- Regular use of immunosuppressive medication (e.g. corticosteroids (except inhaled))
•- Pregnancy, breastfeeding period
•- Alcohol, drug and/or medication abuse
•- Immediate need for surgical intervention in the next 3 months
•- Simultaneous participation in another clinical trial or participation within the last 30 days
•- Study participants not capable of giving informed consent
•- Refusal or withdrawal of consent by study participants

发起方

pfit GmbH & Co. KG